FDA approves new drug for anthrax poisoning


Save Story

Estimated read time: Less than a minute

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

WASHINGTON (AP) — Federal health officials say they have approved an infusible drug to treat patients who have been exposed to anthrax.

The Food and Drug Administration approved Anthrasil for use in combination with older antibiotics to treat inhalation anthrax, which can cause serious injury and death. The condition occurs when the bacterial spores that carry anthrax are inhaled.

Anthrasil is made from the blood plasma of people who have been vaccinated against anthrax. They carry antibodies against the toxic bacteria.

The drug's development was funded by the U.S. government's Biomedical Advanced Research and Development Authority, which stockpiles vaccines, drugs and equipment for use during pandemics and other health emergencies.

The FDA approved the drug based efficacy data from animal studies and human safety studies. It is manufactured by Cangene Corporation of Canada.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Most recent Business stories

Related topics

The Associated Press

    STAY IN THE KNOW

    Get informative articles and interesting stories delivered to your inbox weekly. Subscribe to the KSL.com Trending 5.
    By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Notice.
    Newsletter Signup

    KSL Weather Forecast

    KSL Weather Forecast
    Play button